| [2] |
ENgstrand J, Nilsson H, Strömberg C, et al. Colorectal cancer liver metastases - a population-based study on incidence, management and survival [J]. BMC cancer, 2018, 18(1): 78.
|
| [3] |
Giannis D, Sideris G, Kakos CD, et al. The role of liver transplantation for colorectal liver metastases: A systematic review and pooled analysis [J]. Transplant Rev (Orlando), 2020, 34(4): 100570.
|
| [4] |
Dmello RS, To SQ, Chand AL. Therapeutic targeting of the tumour microenvironment in metastatic colorectal cancer [J]. Int J Mol Sci, 2021, 22(4): 2067.
|
| [5] |
Sabanathan D, Eslick GD, Shannon J. Use of neoadjuvant chemotherapy plus molecular targeted therapy in colorectal liver metastases: a systematic review and meta-analysis [J]. Clin Colorectal Cancer, 2016, 15(4): e141-e147.
|
| [6] |
Primrose J, Falk S, Finch-jones M, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial [J]. The Lancet Oncology, 2014, 15(6): 601-611.
|
| [7] |
Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J]. N Engl J Med, 2004, 350(23): 2335-2342.
|
| [8] |
Tomasello G, Petrelli F, Ghidini M, et al. FOLFOXIRI plus bevacizumab as conversion therapy for patients with initially unresectable metastatic colorectal cancer: a systematic review and pooled analysis [J]. JAMA Oncology, 2017, 3(7): e170278.
|
| [9] |
Ye LC, Liu TS, Ren L, et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases [J]. J Clin Oncol, 2013, 31(16): 1931-1938.
|
| [10] |
Lenz HJ, Ou FS, Venook AP, et al. Impact of consensus molecular subtype on survival in patients with metastatic colorectal cancer: results from CALGB/SWOG 80405 (Alliance) [J]. J Clin Oncol, 2019, 37(22): 1876-1885.
|
| [11] |
Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial [J]. Lancet (London, England), 2013, 381(9863): 303-312.
|
| [12] |
Shitara K, Yamanaka T, Denda T, et al. REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients [J]. Ann Oncology, 2019, 30(2): 259-265.
|
| [13] |
Li J, Qin S, Xu RH, et al. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: The FRESCO randomized clinical trial [J]. JAMA, 2018, 319(24): 2486-2496.
|
| [14] |
Stintzing S, Heinrich K, Tougeron D, et al. Randomized study to investigate FOLFOXIRI plus either bevacizumab or cetuximab as first-line treatment of BRAF V600E-mutant mCRC: The phase-II FIRE-4.5 study (AIO KRK-0116) [J]. Journal of Clinical Oncology, 2021, 39(15): 3502.
|
| [15] |
Grothey A, Fakih M, Tabernero J. Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines [J]. Ann Oncol, 2021, 32(8): 959-967.
|
| [16] |
Tabernero J, Grothey A, Van Cutsem E, et al. Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study [J]. Journal of Clinical Oncology, 2021, 39(4): 273-284.
|
| [17] |
Van Cutsem E, Huijberts S, Grothey A, et al. Binimetinib, encorafenib, and cetuximab triplet therapy for patients with BRAF V600E-mutant metastatic colorectal cancer: safety lead-in results from the phase Ⅲ BEACON colorectal cancer study [J]. Journal of Clinical Oncology, 2019, 37(17): 1460-1469.
|
| [18] |
Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer [J]. N Engl J Med, 2019, 381(17): 1632-1643.
|
| [19] |
André T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer [J]. N Engl J Med, 2020, 383(23): 2207-2218.
|
| [20] |
Overman MJ, Mcdermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study [J]. The Lancet Oncology, 2017, 18(9): 1182-1191.
|
| [21] |
Parry RV, Chemnitz JM, Frauwirth KA, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms [J]. Molecular and Cellular Biology, 2005, 25(21): 9543-9553.
|
| [22] |
Chen EX, Jonker DJ, Loree JM, et al. Effect of combined immune checkpoint inhibition vs best supportive care alone in patients with advanced colorectal cancer: The Canadian Cancer Trials Group CO.26 Study [J]. JAMA Oncology, 2020, 6(6): 831-838.
|
| [23] |
Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity [J]. CA: A Cancer Journal for Clinicians, 2020, 70(2): 86-104.
|
| [24] |
Prieux-klotz C, Dior M, Damotte D, et al. Immune checkpoint inhibitor-induced colitis: diagnosis and management [J]. Targeted Oncology, 2017, 12(3): 301-308.
|
| [25] |
Zen Y, Yeh MM. Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury [J]. Mod Pathol, 2018, 31(6): 965-973.
|
| [26] |
Kao JC, Brickshawana A, Liewluck T. Neuromuscular complications of programmed cell death-1 (PD-1) Inhibitors [J]. Curr Neurol Neurosci Rep, 2018, 18(10): 63.
|
| [27] |
Kalyan A, Kircher S, Shah H, et al. Updates on immunotherapy for colorectal cancer [J]. J Gastrointest Oncol, 2018, 9(1): 160-169.
|
| [28] |
Nami S, Mohammadi R, Vakili M, et al. Fungal vaccines, mechanism of actions and immunology: A comprehensive review [J]. Biomed Pharmacother, 2019, 109: 333-344.
|
| [29] |
Ramsay RG, Gonda TJ. MYB function in normal and cancer cells [J]. Nature Reviews Cancer, 2008, 8(7): 523-534.
|
| [30] |
Cross RS, Malaterre J, Davenport AJ, et al. Therapeutic DNA vaccination against colorectal cancer by targeting the MYB oncoprotein [J]. Clin Transl Immunology, 2015, 4(1): e30.
|
| [31] |
Yu I, Dakwar A, Takabe K. Immunotherapy: recent advances and its future as a neoadjuvant, adjuvant, and primary treatment in colorectal cancer [J]. Cells, 2023, 12(2): 258.
|
| [32] |
Mohme M, Neidert MC, Regli L, et al. Immunological challenges for peptide-based immunotherapy in glioblastoma [J]. Cancer Treat Rev, 2014, 40(2): 248-258.
|
| [33] |
Santos PM, Butterfield LH. Dendritic cell-based cancer vaccines[J]. J Immunol, 2018, 200(2): 443-449.
|
| [1] |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA: A Cancer Journal for Clinicians, 2018, 68(6): 394-424.
|
| [34] |
Kaufman HL, Lenz HJ, Marshall J, et al. Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer [J]. Clin Cancer Res, 2008, 14(15): 4843-4849.
|
| [35] |
Cho JA, Lee YS, Kim SH, et al. MHC independent anti-tumor immune responses induced by Hsp70-enriched exosomes generate tumor regression in murine models[J]. Cancer Lett, 2009, 275(2): 256-265.
|
| [36] |
Dai S, Wei D, Wu Z, et al. Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer [J]. Mol Ther, 2008, 16(4): 782-790.
|
| [37] |
Ruella M, Kalos M. Adoptive immunotherapy for cancer [J]. Immunological Reviews, 2014, 257(1): 14-38.
|
| [38] |
Turin I, Delfanti S, Ferulli F, et al. In vitro killing of colorectal carcinoma cells by autologous activated NK cells is boosted by anti-epidermal growth factor receptor-induced ADCC regardless of RAS mutation status [J]. Journal of Immunotherapy (Hagerstown, Md: 1997), 2018, 41(4): 190-200.
|
| [39] |
Schubert ML, Schmitt M, Wang L, et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy [J]. Ann Oncology, 2021, 32(1): 34-48.
|
| [40] |
Parkhurst MR, Yang JC, Langan RC, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis [J]. Mol Ther, 2011, 19(3): 620-626.
|
| [41] |
Nguyen M, Tipping SMITH S, Lam M, et al. An update on the use of immunotherapy in patients with colorectal cancer [J]. Expert Rev Gastroenterol Hepatol, 2021, 15(3): 291-304.
|
| [42] |
Bacac M, Fauti T, Sam J, et al. A novel carcinoembryonic antigen T-Cell bispecific antibody (CEA TCB) for the treatment of solid tumors [J]. Clin Cancer Res, 2016, 22(13): 3286-3297.
|
| [43] |
Bacac M, Klein C, Umana P. CEA TCB: A novel head-to-tail 2∶1 T cell bispecific antibody for treatment of CEA-positive solid tumors [J]. Oncoimmunology, 2016, 5(8): e1203498.
|
| [44] |
Wang J, Lou HM, Cai HB, et al. A study of AK104 (an anti-PD1 and anti-CTLA4 bispecific antibody) combined with standard therapy for the first-line treatment of persistent, recurrent, or metastatic cervical cancer (R/M CC) [J]. Journal of Clinical Oncology, 2022, 40(16): 106.
|
| [45] |
Dovedi SJ, Elder MJ, Yang C, et al. Design and efficacy of a monovalent bispecific PD-1/CTLA4 antibody that enhances CTLA4 blockade on PD-1(+) activated T cells [J]. Cancer Discovery, 2021, 11(5): 1100-1117.
|
| [46] |
Geevarghese SK, Geller DA, De Haan HA, et al. Phase Ⅰ/Ⅱ study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver [J]. Human Gene Therapy, 2010, 21(9): 1119-1128.
|
| [47] |
Markman JL, Shiao SL. Impact of the immune system and immunotherapy in colorectal cancer [J]. Journal of Gastrointestinal Oncology, 2015, 6(2): 208-223.
|
| [48] |
Lynch D, Murphy A. The emerging role of immunotherapy in colorectal cancer[J]. Ann Transl Med, 2016, 4(16): 305.
|
| [49] |
Ciardiello D, Vitiello PP, Cardone C, et al. Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy [J]. Cancer Treatment Reviews, 2019, 76: 22-32.
|
| [50] |
Pitt JM, Marabelle A, Eggermont A, et al. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy [J]. Ann Oncol, 2016, 27(8): 1482-1492.
|
| [51] |
Milette S, Sicklick JK, Lowy AM, et al. Molecular pathways: targeting the microenvironment of liver metastases [J]. Clinical Cancer Research, 2017, 23(21): 6390-6399.
|
| [52] |
Sarvizadeh M, Ghasemi F, Tavakoli F, et al. Vaccines for colorectal cancer: an update [J]. Journal of Cellular Biochemistry, 2019, 120(6): 8815-8828.
|
| [53] |
Lomax AJ, Lim J, Cheng R, et al. Immune toxicity with checkpoint inhibition for metastatic melanoma: case series and clinical management [J]. Journal of Skin Cancer, 2018, 2018: 9602540.
|
| [54] |
Simeone E, Grimaldi AM, Festino L, et al. Immunotherapy in metastatic melanoma: a novel scenario of new toxicities and their management [J]. Melanoma Management, 2019, 6(4): Mmt30.
|
| [55] |
Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper [J]. Ann Oncology, 2016, 27(4): 559-574.
|